# Dysferlinopathy Fibroblasts Are Defective in Plasma Membrane Repair

**Authors:** Chie Matsuda, Kazuyuki Kiyosue, Ichizo Nishino, Yuichi Goto, Yukiko K. Hayashi

PMC · DOI: 10.1371/currents.md.5865add2d766f39a0e0411d38a7ba09c · 2015-10-29

## TL;DR

Fibroblasts from dysferlinopathy patients and SJL mice show impaired membrane repair, suggesting they can be used to study this condition.

## Contribution

This study demonstrates that fibroblasts, not just muscle cells, can be used as a model for studying dysferlinopathy.

## Key findings

- Dysferlin-deficient fibroblasts from patients and SJL mice show defective plasma membrane repair.
- Membrane blebbing in response to hypotonic shock is absent in dysferlin-deficient fibroblasts.
- Proteasomal inhibition can partially restore dysferlin levels and membrane blebbing in some cases.

## Abstract

Background: Dysferlin is a sarcolemmal protein that is defective in Miyoshi myopathy and limb-girdle muscular dystrophy type 2B, and is involved in sarcolemmal repair. Primary cultured myoblasts and myotubes established from patient muscle biopsies have been widely utilized to explore the molecular mechanism of dysferlinopathy.

Objectives: The purpose of this study was to explore the possible utility of dermal fibroblasts from dysferlin-deficient patients and SJL mice as a tool for studying dysferlinopathy.

Methods: Dysferlin protein expression in fibroblasts from dysferlin-deficient patients and SJL mice was analyzed by immunoblotting and immunocytochemistry. The membrane wound-repair assay was performed on the fibroblasts using a confocal microscope equipped with a UV-laser. The membrane blebbing assay using hypotonic shock, in which normal membrane blebbing is detected only in the presence of dysferlin, was also performed using human and mouse fibroblasts.

Results: Mis-sense mutated dysferlin was expressed at a very low level in fibroblasts from a dysferlinopathy patient, and lower expression level of truncated dysferlin was observed in SJL mouse fibroblast. Fibroblasts from patients with dysferlinopathy and SJL mice showed attenuated membrane repair and did not form membrane blebs in response to hypoosmotic shock. Proteosomal inhibitior increased mis-sense mutated or truncated dysferlin levels, and restored membrane blebbing, however, proteosomal inhibition failed to improve levels of dysferlin with non-sense or frame-shift mutation.

Conclusion: Fibroblasts from dysferlinopathy patients and SJL mice showed attenuated plasma membrane repair, and could be a tool for studying dysferlinopathy.

## Linked entities

- **Genes:** FER1L5 (fer-1 like family member 5) [NCBI Gene 102083753]
- **Proteins:** FER1L5 (fer-1 like family member 5)
- **Diseases:** Miyoshi myopathy (MONDO:0009685), limb-girdle muscular dystrophy type 2B (MONDO:0009676), dysferlinopathy (MONDO:0016145)
- **Species:** Homo sapiens (taxon 9606), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, MYOD1 (myogenic differentiation 1) [NCBI Gene 4654] {aka CMYO17, CMYP17, MYF3, MYOD, MYODRIF, PUM}, DYSF (dysferlin) [NCBI Gene 8291] {aka FER1L1, LGMD2B, LGMDR2, MMD1}, Lamp2 (lysosomal-associated membrane protein 2) [NCBI Gene 16784] {aka CD107b, LGP-B, Lamp II, Lamp-2, Lamp-2a, Lamp-2b}, Dysf (dysferlin) [NCBI Gene 26903] {aka 2310004N10Rik, D6Pas3}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}
- **Diseases:** distal anterior compartment myopathy (MESH:D000868), Hypotonic shock (MESH:D012769), myopathies (MESH:D009135), congenital muscular dystrophy (MESH:D009136), skin abnormalities (MESH:D012868), Dysferlinopathy (MESH:C537995), dysferlin deficiency (MESH:D007153), LGMD2B (MESH:C535899), muscle degeneration (MESH:D009410), MM (MESH:C537480), Ullrich congenital muscular dystrophy (MESH:C537521)
- **Chemicals:** lactacystin (MESH:C067713), glycerol (MESH:D005990), bromophenol blue (MESH:D001978), FM 1-43 (MESH:C073804), MgCl2 (MESH:D015636), HEPES (MESH:D006531), CO2 (MESH:D002245), polyacrylamide (MESH:C016679), HCl (MESH:D006851), bortezomib (MESH:D000069286), SDS (MESH:D012967), Triton X-100 (MESH:D017830), KCl (MESH:D011189), paraformaldehyde (MESH:C003043), CaCl2 (MESH:D002122), 2-mercaptoethanol (MESH:D008623), NaCl (MESH:D012965), PBS (MESH:D007854), water (MESH:D014867), Ca2+ (-), MG-132 (MESH:C072553)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** R555W, W999C, c.1566C>G, c.5698_5699delAG, Y522X, R1607X, 1566C>G, G>T, 5699delAG
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), SJL — Mus musculus (Mouse), Finite cell line (CVCL_5897), SJL/6J — Mus musculus (Mouse), Finite cell line (CVCL_5896), COS-7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4639325/full.md

---
Source: https://tomesphere.com/paper/PMC4639325